In this study, we found that the expression of TRIM33 was upregulated in Ang II–induced fibrotic myocardium and CFs, but there was no significant change in cardiomyocytes, indicating that Trim33 may be a functional therapeutic target in the occurrence and development of myocardial fibrosis. Here, TRIM33 is linked to Myocardial fibrosis.